Equillium reports Q2 EPS (35c), consensus (34c)
As of June 30, Equillium reported total cash, cash equivalents and short-term investments of $56.9M, compared to $65.9M as of December 31, 2018. "Since our last quarterly update, we took significant steps forward in the clinical development of our lead therapeutic candidate, itolizumab, with the initiation of the Phase 1b EQUIP proof-of-concept trial for the treatment of uncontrolled asthma, and acceptance of our IND application by the FDA for the treatment of lupus nephritis," stated Daniel Bradbury, chairman and chief executive officer of Equillium. "With two clinical trials now up and running, and a third trial in lupus nephritis planned to commence later this year, we are well positioned to establish the broad clinical utility of itolizumab on our path toward helping improve the lives of patients with severe immuno-inflammatory disorders. We look forward to several important clinical milestones through the end of 2020."